51 results about "Lung squamous cell carcinoma" patented technology

The invention discloses a lung squamous cell carcinoma survival prediction method and system based on SHAP interpretability, and relates to the technical field of medical data analysis. Comprising the following steps: constructing a dynamically updated physiological feature information table based on a lung squamous cell carcinoma clinical data set of a target under multiple time nodes; and associating different survival analysis models with the physiological feature information table to predict the survival probability of the lung squamous cell carcinoma in the target body, the marginal contribution of each input feature to the output of each model is obtained by using the SHAP interpretation algorithm, and the feature uniqueness score is transparently displayed in the fusion process, so that the survival probability of the lung squamous cell carcinoma in the target body can be predicted in the actual use process. The method can visually understand how each feature affects the final prediction, and achieves automatic arbitration or manual recheck through providing a model to explain conflict measurement, invalid variable elimination and pseudo high risk verification and weighted scoring, thereby guaranteeing the reasonability and safety of prediction and intervention suggestions, reducing the decision risk, and enhancing the clinical trust.

The invention discloses a lung squamous cell carcinoma survival probability prediction system fusing multiple models, and relates to the technical field of medical data analysis. Comprising a data acquisition module used for acquiring a lung squamous carcinoma clinical data set and an inspection index of a patient; the data preprocessing and dynamic feature table construction module is used for preprocessing the lung squamous cell carcinoma clinical data set in existing data processing and dynamically updating a physiological feature information table; the model training and predicting module is used for carrying out training and online prediction on various survival analysis models; and the SHAP interpretation and weight calculation module is used for calling a corresponding SHAP algorithm to obtain an average absolute SHAP value of each input feature. According to the method, model interpretation conflict measurement, invalid variable elimination and pseudo high risk verification are provided, and automatic arbitration or artificial recheck is realized through weighted scoring, so that the reasonability and safety of prediction and intervention suggestions are ensured, the decision risk is reduced, and the clinical trust is enhanced.

The invention discloses a micromolecule NSD3 degradation agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a micromolecular NSD3 degradation agent, which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The small molecule NSD3 degradation agent provides a new scheme for treatment of lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

In alternative embodiments, provided are chimeric, synthetic or recombinant antibodies (Ab) against the human homologous box NKX-2. 1 (also known as NK2 homologous box 1, or thyroid transcription factor 1 (TTF-1)) protein, including articles of manufacture and kits comprising them, and methods of making and using them, including, for example, their use in the detection or diagnosis and treatment of cancer. In alternative embodiments, an anti-NKX-2. 1 (TTF-1) antibody provided herein is used with an agent for determining whether NKX-2. 1 (TTF-1) expression or activity is present, reduced or deleted; or the sensitivity of the specific binding of the Ab or the antigen (Ag) binding fragment or protein (ABP) or the monomer or dimer ABP provided by the invention with the squamous cell carcinoma cells is lower than the sensitivity of the specific binding with the adenocarcinoma cells (or binding with lower affinity), so that false positives of the squamous cell carcinoma are less, and the positive recognition of the lung adenocarcinoma is better.

The invention discloses a lung squamous cell carcinoma drug discovery method and system based on disturbance response scanning analysis, and belongs to the field of biological medicines.The method comprises the steps that lung squamous cell carcinoma protein expression profile data is downloaded and preprocessed, a robust network module is constructed and multi-scale analysis and evaluation are conducted, and drug genomic data are obtained based on drug genomic data. Predicting the drug sensitivity of the patient by using machine learning, and generating a DRN through difference analysis of the drug sensitivity; predicting drug-target protein binding affinity in combination with deep learning, quantifying node sensitivity through a PRS technology, calculating a DPI disturbance score and ranking drug priorities; high-ranking drugs are screened through comprehensive sensitivity analysis and literature investigation; a drug for a lung squamous carcinoma cell line is screened out through a pre-experiment and is relocated. According to the framework developed by the invention, by integrating proteomics, pharmacogenomics and dynamic network analysis, systematic analysis is provided for relocation drug identification of lung squamous cell carcinoma, and good news is brought to treatment of lung squamous cell carcinoma.

The invention discloses a compound as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a compound which has a structure as shown in a formula I or a formula II, has a remarkable inhibition effect on NSD3 protein expression, and has remarkable killing and growth inhibition effects on lung squamous carcinoma cells. The compound provided by the invention provides a new scheme for treating lung squamous cell carcinoma, and has a good clinical application prospect. # imgabs0 # imgabs1 #

The invention discloses an autoantibody reagent for screening early-stage lung squamous cell carcinoma. The autoantibody comprises autoantibodies of tumor-associated antigens: RNF43; or, RNF43 and KLF4; or, RNF43, KLF4, and P53; or, RNF43, KLF4, P53 and NCOR1, or, RNF43, KLF4, P53 and NCOR1; or, RNF43, KLF4, P53, NCOR1, and CCND1 are selected from the group consisting of: RNF43, KLF4, P53, the reagent provided by the invention is used for detecting the expression level of the antibody in a human body, can effectively detect the lung squamous cell carcinoma, especially early lung squamous cell carcinoma, has high sensitivity and specificity, and can enable the sensitivity to be up to 62.4% and the specificity to be up to 82.3% when the combination of RNF43, KLF4, P53, NCOR1 and CCND1 is used for diagnosing the early lung squamous cell carcinoma. Meanwhile, compared with other combinations, the Youden index is closer to 1, which shows that the combination has higher diagnostic value and higher application value.

The invention relates to the technical field of microorganisms, and particularly discloses a product for predicting tumor cell occurrence and metastasis risks and treating tumors by using a microbial marker. The cancers related to the invention comprise colon adenocarcinoma, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, lung squamous cell carcinoma, prostate adenocarcinoma, gastric adenocarcinoma, thyroid carcinoma, breast invasive carcinoma, uveal melanoma, esophageal carcinoma and the like. As a marker for predicting the occurrence and metastasis risk of tumor cells. The invention also screens specific microorganisms of healthy tissues relative to tumor tissues as potential means for treating tumors. The screened flora marker is high in sensitivity and good in specificity, and a new method is provided for tumor cell generation and metastasis monitoring and tumor treatment.

The invention discloses a lung cancer high-risk group screening questionnaire cognitive calculation correction method and system. The method comprises the following steps: acquiring questionnaire text data of a subject; constructing a BERT-QA model based on the clinical term knowledge graph, analyzing questionnaire text semantics, and extracting structured risk factor data; mapping the risk factor data to a topological space, and constructing a risk topological representation; calculating a dynamic weight coefficient of each risk factor based on an information entropy principle, and generating a risk assessment value of entropy weight optimization; carrying out calibration in combination with regional pollution map data; according to the method, deep learning, topology and fuzzy logic technologies are fused, intelligent analysis of questionnaire texts and dynamic weight calculation of risk factors are realized, environmental pollution factors are effectively integrated, the screening accuracy and individuation level are improved, and the method is suitable for large-scale popularization and application. The method provides technical support for accurate identification and early intervention of lung cancer high-risk groups, and has important clinical application value.

The invention discloses application of lncRNASEH1-AS1 as a target in preparation of a medicine for treating lung squamous cell carcinoma, and belongs to the technical field of biological medicine. The invention finds that the expression of the lncRNASEH1-AS1 in tissues, plasma and cell lines of a lung squamous cell carcinoma patient is higher than that of a control group of the lung squamous cell carcinoma patient. The lncRNASEH1-AS1 has clinical correlation with the tumor diameter of a lung squamous cell carcinoma patient. The results of CCK-8, clone formation, Transwell migration and invasion experiments show that after the lncRNASEH1-AS1 and the MCM7 are knocked down, the proliferation, migration and invasion ability of the lung squamous cell carcinoma cells is weakened, and after the lncRNASEH1-AS1 is over-expressed, the inhibition of the MCM7 on the proliferation, migration and invasion ability of the lung squamous cell carcinoma cells can be reversely knocked down. The result of a nude mouse subcutaneous tumor formation experiment shows that the tumor formation capability of the LUSC cells which stably knock down the lncRNASEH1-AS1 is weakened.

The application discloses radix sophorae tonkinensis polysaccharide STGP-1, a preparation method thereof and pharmaceutical use for treating lung squamous carcinoma, and relates to the technical field of medicines. The monosaccharide composition of STGP-1 includes fucose Fuc, arabinose Ara, galactose Gal, glucose Glc, xylose Xyl and mannose Man, and the molar ratio is 0.34:12.15:25.76:57.07:1.06:3.62. The STGP-1 is obtained by extraction, separation and purification from dried roots and rhizomes of radix sophorae tonkinensis, and the preparation method comprises the steps of pretreatment and crude extraction, impurity removal treatment, anion exchange column chromatography separation, gel column chromatography purification and the like. The STGP-1 can be used alone or in combination with anti-PD-1 monoclonal antibody for preparing a medicine for treating lung squamous carcinoma. The preparation process is stable, the source is natural, and the STGP-1 can provide a new high-efficiency and low-toxicity candidate medicine for immune combined treatment of lung squamous carcinoma.

The invention provides a lung squamous cell carcinoma organoid culture medium and a culture method. The lung squamous cell carcinoma organoid culture medium is prepared from the following components: R-spondin-1, Noggin, EGF (Epidermal Growth Factor), FGF10 (Fibroblast Growth Factor), FGF7 (Fibroblast Growth Factor), A83-01, Y-27632, Nicotinamide, Insulin, B27 Supplement, N-Acetylcysteine, Alpisib, GlutaMAX, primary cell antibiotics and the like. The lung squamous cell carcinoma organoid culture medium can be used for efficiently culturing lung squamous cell carcinoma tissues and successfully obtaining organoid, the formed organoid is highly similar to primary lung squamous cell carcinoma tissues in cell type, polarity and spatial hierarchical structure, and the micropathologic characteristics of tumors are truly reproduced. And the organoid can be stably passaged for a long time, so that an ideal and reliable preclinical model is provided for pathogenesis research, personalized drug screening and novel therapy development of lung squamous cell carcinoma.

The invention relates to the technical field of biology, in particular to a single nucleotide polymorphism site marker composition for predicting postoperative recurrence and metastasis risks of lung squamous cell carcinoma patients and application of the single nucleotide polymorphism site marker composition. The risk of recurrence and metastasis of lung squamous cell carcinoma patients after radical treatment (operation and radiofrequency ablation) can be accurately predicted, and a more positive and effective treatment scheme is formulated for patients with poor prognosis, so that individualized treatment of the patients is realized, and the survival rate is increased. The invention further provides a kit for predicting the postoperative recurrence and metastasis risk of the lung squamous cell carcinoma patient, and the kit provided by the invention can be used for assisting and guiding individualized treatment and improving prognosis of the lung squamous cell carcinoma patient by detecting SNP sites on peripheral blood DNA or lung squamous cell carcinoma tissue DNA of the lung squamous cell carcinoma patient.

The present invention provides a lung squamous cell carcinoma patient immunotherapy effect prediction device, which comprises a detection unit and a data analysis unit, the detection unit extracts 9 types of intra-tumor bacteria as characteristic intra-tumor bacteria based on 16S rRNA sequencing data of a lung squamous cell carcinoma patient tumor puncture sample; the data analysis unit is used for constructing a data model for predicting the curative effect of immunotherapy on the basis of 16S rRNA sequencing data of tumor puncture samples of the characteristic intra-tumor bacteria and lung squamous cell carcinoma patients; the characteristic intra-tumorous bacteria comprise a plasmobacterium actinomycetes genus, an anaerobic bacillus genus, a kantobacterium genus, a Vinci bacterium genus, a kocuria genus, a freshwater bacterium genus, a microbacterium genus, an achromobacter genus and a proteus genus; the prediction device can predict whether immunotherapy of lung squamous cell carcinoma patients is effective or not, screening and hierarchical management can be conducted on the patients before treatment, and therefore individualized medication is guided, and the curative effect is improved.

The invention relates to the technical field of biological medicine, and particularly discloses a lipidosome targeting SELENOP + macrophages, a preparation method of the lipidosome and application of the lipidosome in lung squamous cell carcinoma treatment. According to the lipidosome, an SELENOP antibody is used as a targeted modification molecule, si-SELENOP and s-ABCA1 / G1 are loaded, and accurate delivery of siRNA in target cells is achieved through specific binding of the antibody and a SELENOP receptor on the surface of a SELENOP + macrophage. The targeting liposome prepared by the invention can specifically inhibit cholesterol efflux pathways of SELENOP + macrophages, reverse tumor phenotypic polarization, remodel a tumor immune microenvironment and recover anti-tumor activity of immune cells such as CD8 + T cells, NK cells and the like. When the liposome is independently used or combined with a PD-1 antibody, the growth and metastasis of the lung squamous cell carcinoma can be remarkably inhibited, the treatment effect is improved, a brand new metabolism-immunity synergistic targeted treatment strategy is provided for the lung squamous cell carcinoma, and the liposome has a good clinical application prospect.

This invention provides the use of CX6258 or its salts in medicaments for the prevention and / or treatment of lung cancer, belonging to the field of biomedicine. This invention is the first to discover that CX6258HCl can effectively inhibit the growth of lung squamous cell carcinoma cell lines and organoids, and that CX6258HCl can also be combined with cisplatin to treat lung squamous cell carcinoma. Therefore, CX6258 or its salts have broad application prospects in medicaments for the prevention and / or treatment of lung cancer, especially lung squamous cell carcinoma.

The invention discloses HD (at) NitC (at) MOF nanoparticles as well as a preparation method and application thereof. The preparation method comprises the following steps: mixing a ferrous sulfate heptahydrate solution and an oxsalazine solution to obtain a mixed solution, and reacting the mixed solution under a closed condition to obtain MOF; the preparation method comprises the following steps: respectively dissolving nitidine chloride and MOF in methanol, mixing and reacting to obtain NitC (at) MOF; the preparation method comprises the following steps: adding EDC and NHS into a hyaluronic acid solution for reaction, and dropwise adding a DOPA solution into a reaction solution for reaction to obtain HA-DOPA; the preparation method comprises the following steps: dissolving HA-DOPA in deionized water, and then adding NitC (at) MOF for reaction to obtain a final product. The HD (at) NitC (at) MOF has a good killing effect on SK-MES-1 cells, can induce the generation of ROS (reactive oxygen species) and the consumption of GSH (glutathione), and can induce ferroptosis and necroptosis of the SK-MES-1 cells, so that a new strategy is provided for the treatment of squamous cell carcinoma of lung.

The invention belongs to the field of biological medicine, and particularly relates to a reagent and a kit for detecting lung squamous cell carcinoma and application. According to the kit for detecting lung squamous cell carcinoma, lung squamous cell carcinoma subjects and healthy subjects can be effectively distinguished by detecting the methylation level of the target region of the DLX2-AS1 gene in a sample, a biomarker capable of being used for lung squamous cell carcinoma detection is provided, and the sensitivity and specificity of lung squamous cell carcinoma detection are improved while non-invasive detection is achieved.

The application relates to the fields of cell biology and biological medicine technology, and specifically discloses a kind of co-culture system construction method based on TGM2 target regulation mesenchymal stem cells and co-culture system prepared by the method. The method comprises the following steps: preparing human umbilical cord mesenchymal stem cells, lung adenocarcinoma cells A549 and lung squamous carcinoma cells SW1573 in logarithmic growth phase respectively; mixing A549 and SW1573 cells according to a 1:1 ratio to obtain mixed lung cancer cells; mixing hUC-MSC and mixed lung cancer cells according to a quantity ratio of 5:1 to 13:1, inoculating in a culture vessel containing culture medium, and culturing at 37 DEG C under a 5% CO2 condition for 3-9 days to obtain the co-culture system. The application does not need to genetically modify hUC-MSC, and by optimizing the co-culture ratio and time, using natural communication between cells, the proliferation, migration and invasion of lung cancer cells can be effectively inhibited, and cell cycle arrest and apoptosis can be induced.

A product for diagnosing lung cancer, wherein the product comprises a reagent used for detecting a biomarker in a subject sample, and the biomarker includes PCDH18, CDKN2A and / or HOXA9. The reagent used for determining expression level of the biomarker on the subject sample by quantitative PCR, NGS, Northern blot, Southern blot, microarray, SAGE, immunoassay or mass spectrometry. Methods of immunoassay include ELISA, EIA, agglutination test, nephelometry, turbidimetry, Western blot, immunoprecipitation, immunocytochemistry, flow cytometry and Luminex assay. The reagent comprises a primer, probe and an antibody and the product comprises a kit, nucleic acid membrane strip, a preparation and a chip. The lung cancer may be lung squamous cell carcinoma.

The invention belongs to the technical field of molecular markers, and particularly relates to application of FGFBP2 as a lung squamous cell carcinoma diagnosis marker. The invention provides a biomarker for lung squamous cell carcinoma diagnosis, the biomarker is FGFBP2 gene or FGFBP2 protein, the content of the marker in serum of a lung squamous cell carcinoma patient is remarkably increased, the expression level of the marker in lung squamous cell carcinoma tissue is remarkably higher than that of a normal person, and the difference has statistical significance. By detecting the expression level of FGFBP2 in human serum, lung squamous cell carcinoma patients and normal people can be effectively distinguished, and the FGFBP2 can be used for diagnosing lung squamous cell carcinoma.

The application discloses application of a pathogenic transposable element pL1HS as a lung squamous carcinoma biomarker and a therapeutic target. The 5'-UTR region of the pathogenic transposable element pL1HS has a nucleic acid sequence as shown in SEQ ID NO. 1, and specific detection primers are shown in SEQ ID NO. 2 and SEQ ID NO. 3 respectively. Animal experiments prove that the combined application of the reverse transcription transposition inhibitor nevirapine and the cGAS inhibitor can significantly inhibit the growth of lung squamous carcinoma. The pathogenic transposable element pL1HS can be used as a novel molecular marker in the diagnostic application dimension, and provides a precise detection index for early screening, pathological typing and prognosis judgment of lung squamous carcinoma. In the treatment application dimension, the target intervention strategy for pL1HS, especially the combined medication scheme of multi-pathway inhibitors, opens up a new direction.

The invention provides a CA-4 piperazine derivative as well as a preparation method and application thereof, and relates to the field of chemical medicines. The structural formula of the CA-4 piperazine derivative is as shown in formula (1), when R1 is F, R2 is OCH3, and R3 is one of F, Cl, Br, CH3 and OCH3; when R1 is H, R2 is OCH3 or SCH3, and R3 is one of F, Cl, Br, CH3 and OCH3. According to the invention, the Combretastatin A-4 (CA-4) derivative is synthesized and prepared, compounds 32-46 are 15 new compounds, and research finds that the compounds 32-46 have an obvious inhibition effect on 4 tumor cells, and can be applied to preparation of vascular targeting preparation medicines for treating colorectal cancer, lung adenocarcinoma, gastric cancer and lung squamous carcinoma.

The invention belongs to the field of RNA medicine development, and particularly relates to application of FGFBP2 in preparation of a medicine for treating lung squamous cell carcinoma. According to the present invention, the research results show that the FGFBP2 has significant high expression in lung squamous cell carcinoma tissues, and the expression or the activity of the FGFBP2 is inhibited through the recombinant adeno-associated virus rAAV5-FGFBP2 shRNA (rAAV5-shFGFBP2.1, rAAV5-shFGFBP2.2) specifically targeting the FGFBP2 gene, and the siRNA specifically targeting the FGFBP2 gene, such that the expression of the FGFBP2 protein can be significantly inhibited; therefore, the FGFBP2 can be used as a drug, a drug target or a target gene in gene therapy, and is applied to relieving and / or treating the lung squamous cell carcinoma.

This invention relates to the pharmaceutical applications of MRPS7 as a diagnostic biomarker for non-small cell lung cancer (NSCLC) and its inhibitors, belonging to the field of biomedical technology. For the first time, this invention utilizes immunohistochemical analysis of tumor tissues from NSCLC patients and paired adjacent normal tissues to confirm that MRPS7 protein is significantly overexpressed in NSCLC tissues (p<0.001), and this difference is statistically significant in both lung adenocarcinoma and lung squamous cell carcinoma subtypes. Furthermore, this invention demonstrates through in vitro functional experiments that knocking down MRPS7 gene expression using siRNA targeting MRPS7 significantly inhibits the proliferation, migration, and invasion abilities of NSCLC cells (A549, SK-MES-1) (p<0.001). Therefore, reagents for detecting MRPS7 expression levels can be used to prepare NSCLC diagnostic products, and MRPS7 inhibitors can be used to prepare drugs for treating NSCLC. This invention provides a novel molecular biomarker for the diagnosis of NSCLC and a new strategy for targeted therapy of NSCLC.

The invention discloses application of a pathogenic transposon element pL1HS as a lung squamous cell carcinoma biomarker and a treatment target. The 5 '-UTR region of the pathogenic transposon element pL1HS disclosed by the invention has a nucleic acid sequence as shown in SEQ ID NO.1, and specific detection primers of the pathogenic transposon element pL1HS are respectively as shown in SEQ ID NO.2 and SEQ ID NO.3. Animal experiments prove that the growth of lung squamous cell carcinoma can be remarkably inhibited by combined application of the nevirapine as a reverse transcription and transposition inhibitor and the cGAS inhibitor. The pathogenic transposon element pL1HS can be used as a novel molecular marker in the diagnosis application dimension, and provides accurate detection indexes for early screening, pathological typing and prognosis of lung squamous cell carcinoma; in the aspect of treatment application, a new direction is developed for a targeted intervention strategy of pL1HS, especially a combined medication scheme of a multi-channel inhibitor.

The invention relates to the technical field of cell biology and biological medicine, and particularly discloses a co-culture system construction method based on TGM2 targeted regulation of mesenchymal stem cells and a co-culture system prepared by the method. The method comprises the following steps: respectively preparing human umbilical cord mesenchymal stem cells, lung adenocarcinoma cells A549 and lung squamous carcinoma cells SW1573 in a logarithmic phase; mixing A549 and SW1573 cells according to a ratio of 1: 1 to obtain mixed lung cancer cells; and mixing the hUC-MSC and the mixed lung cancer cells according to a quantitative ratio of 5: 1 to 13: 1, inoculating the mixture into a culture container containing a culture medium, and culturing for 3-9 days under the conditions of 37 DEG C and 5% CO2 to obtain the co-culture system. The method does not need to carry out gene modification on hUC-MSC, and can effectively inhibit proliferation, migration and invasion of lung cancer cells and induce the lung cancer cells to generate cell cycle arrest and apoptosis by optimizing the co-culture proportion and time and utilizing natural communication between cells.

The invention discloses application of an RPN1 gene in diagnosis and treatment of lung cancer, and belongs to the technical field of biological diagnosis and biological medicine. Specifically, through comparison of differential genes of healthy individuals and different subtype lung cancer patients in a database, it is found that RPN1 gene RNA and protein expression are ubiquitous and significantly up-regulated, and through verification of different data sets and the like, it is proved that the target spot can be used as a lung cancer detection target spot. The RPN1 gene in the cancer cells is knocked down, it is found that RPN1 knock-down promotes aging of the lung cancer cells, it is shown through in-vivo experiments that reduction of RPN1 expression can improve the severity of the lung cancer, and it is proved that RPN1 can serve as a treatment target of the lung cancer. The invention provides a new diagnosis and treatment target, and provides a new thought and direction for developing a treatment strategy aiming at lung cancer, especially lung adenocarcinoma and lung squamous cell carcinoma in the future.

The invention relates to the technical field of medical treatment, and particularly discloses application of NAE1 in diagnosis, treatment and recurrence prediction of lung squamous cell carcinoma. A biomarker is NAE1 protein or a coding gene thereof, when the expression level of the NAE1 is higher than that in normal tissue, existence of the lung squamous cell carcinoma is indicated, and when the expression level of the NAE1 in the normal tissue is lower than that in the normal tissue, existence of the lung squamous cell carcinoma is predicted. The expression level of the NAE1 is determined by detecting the mRNA level, the protein level or the activity level of the NAE1 in a sample; by detecting the NAE1 expression level, the accuracy of predicting the postoperative recurrence risk of the lung squamous cell carcinoma patient is effectively improved, and the diagnosis and treatment strategy of the patient can be remarkably improved. Meanwhile, the treatment mode taking the NAE1 as the target spot can effectively inhibit the growth and proliferation of lung squamous carcinoma cells, reduce the risk of recurrence and metastasis, and significantly improve the treatment effect and the long-term life quality of patients. In addition, the technical scheme provided by the invention has the advantages of higher precision, definite treatment effect, obvious reduction of serious toxic and side effects caused by the traditional treatment method, simplicity and convenience in operation and obvious clinical application prospect.